ERAS · Erasca, Inc.

Current Thesis

Erasca’s RAS-inhibitor re-rating thesis has broken its published price condition; updated clinical results in November now test whether the underlying drug-development case strengthens. The 2026-09-11 adjusted close of $15.88 breached the $16 weekly-close threshold published on 2026-08-30. That invalidation has occurred; a later recovery would not erase it.

The calendar has improved since the previous note. Erasca’s 2026-09-10 announcement schedules updated ERAS-0015 monotherapy results, with additional patients and longer follow-up, for the 2026-11-18–2026-11-20 symposium in Barcelona. This supersedes the previous framing that no lead-asset update preceded the first half of 2027. Erasca announcement, September 10.

As an inference about the previously published market leg, the narrative is dead — the 2026-09-11 weekly close broke its stated condition despite the newly announced presentation. This describes the price structure, not a clinical finding. A weekly recovery above the July 2026 offering price of $17.50, accompanied by stronger confirmed clinical results, would challenge that assessment.

Bullish and bearish views on Erasca, Inc.

The model's bull view on Erasca, Inc. (ERAS), in brief: Clinical follow-up gains a window. The 2026-09-10 announcement puts additional ERAS-0015 patient observations and follow-up into November 2026. The announcement supplies a test date, but supplies no new efficacy results. Company announcement. Financing precedes further… The bear view: Published price support has failed. The 2026-09-11 adjusted close of $15.88 is below the previously published $16 weekly threshold and the July 2026 offering price of $17.50. The financing reference now sits above the market. Response evidence remains preliminary. The 2026-08-11… Both cases follow in full.

Bull Case

• Clinical follow-up gains a window. The 2026-09-10 announcement puts additional ERAS-0015 patient observations and follow-up into November 2026. The announcement supplies a test date, but supplies no new efficacy results. Company announcement.
• Financing precedes further development. Erasca reported $384.3 million in cash, equivalents and marketable securities at 2026-06-30 and approximately $632.5 million in gross July offering proceeds. Its 2026-08-11 release says available funding covers the listed upcoming milestones; it does not provide a new calendar runway. Second-quarter release.
• Regulatory engagement has advanced. The Food and Drug Administration granted ERAS-0015 Fast Track designation for metastatic pancreatic adenocarcinoma on 2026-08-24. The designation provides development and review benefits subject to applicable criteria; it does not establish efficacy. Erasca Fast Track announcement.

Bear Case

• Published price support has failed. The 2026-09-11 adjusted close of $15.88 is below the previously published $16 weekly threshold and the July 2026 offering price of $17.50. The financing reference now sits above the market.
• Response evidence remains preliminary. The 2026-08-11 release reported a 57% overall response rate, including confirmed and unconfirmed responses, among eligible pancreatic-cancer patients receiving 32 mg daily, using the 2026-05-25 cutoff. The July dataset cited in the prior public note contained seven patients at that dose. That sample is too small to support a durable efficacy claim. Second-quarter release.
• Intellectual-property allegations remain material. Erasca’s 2026-08-11 release identifies Revolution Medicines allegations concerning ERAS-0015 patents or trade secrets among its risks. The disclosure establishes an allegation, not an adjudicated infringement finding. Company risk disclosure.

Setup & Price Structure

The supplied adjusted market series records a $15.88 close on 2026-09-11, 29.3% below its $22.47 trailing-year high, while the three-month price change remained positive at 13.0%. Those observations support a deterioration in the recent structure without establishing a new lower support level.

The public positioning observable is July 2026 issuance at $17.50, now above the September 11 market close. It establishes additional share supply; it does not establish whether offering participants still own those shares. The supplied September 11 observations contain no current ownership, short-interest or fund-flow measurements, so a present crowding verdict is unsupported.

Catalyst Calendar (next 30 days)

• 2026-11-18–2026-11-20, beyond 30 days: Updated ERAS-0015 monotherapy data are scheduled within the Barcelona symposium window announced on 2026-09-10. The clinical question is whether additional observations strengthen response confirmation and tolerability evidence. Company presentation announcement.
• 2026-12-31, guidance deadline: This is the endpoint of the second-half-2026 ERAS-4001 preliminary monotherapy-data window reiterated on 2026-08-11, not a scheduled presentation date. Absence of those data by that date would constitute a missed window. Second-quarter milestone guidance.

Elapsed catalysts

• 2026-09-15: Management’s Morgan Stanley healthcare-conference fireside chat is scheduled for 1:05 p.m. Eastern Time, according to Erasca’s 2026-09-08 announcement. This is a management presentation; the announcement does not promise clinical results. Company conference announcement. (passed 5d ago)

What Would Change Our Mind

The recovery structure already failed: a weekly close below $16 was the published thesis-break condition, and the 2026-09-11 close of $15.88 satisfies it. The threshold remains unchanged rather than being lowered after the breach.

A different assessment would require observable repair: a weekly close above the July 2026 offering reference of $17.50 and confirmed responses supported by the additional patients and follow-up promised on 2026-09-10. Failure to deliver the announced November update, or disclosure that previously reported responses were not confirmed, would undermine that rebuilding case.

Correlation Notes

This remains a single-name clinical setup. The 2026-09-10 announcement concerns Erasca’s own trial, while the supplied 2026-09-11 price observations contain no paired sector-return series. No measured correlation with biotechnology equities or another RAS developer can be stated from that evidence; the thematic tags describe exposure, not demonstrated co-movement.